(MedPage Today) — At the American Society of Nephrology Kidney Week meeting, interim results from the phase III ORIGIN 3 trial showed that investigational atacicept led to a 46% reduction in proteinuria at 36 weeks in patients with immunoglobulin…
Source link : https://www.medpagetoday.com/meetingcoverage/kidneyweekvideopearls/118855
Author :
Publish date : 2025-12-05 17:40:00
Copyright for syndicated content belongs to the linked Source.
